RESUMO
OBJECTIVES: Immunotherapy using recombinant monoclonal antibodies specifically Anti-amyloid-beta (Anti-Aß) scFv is envisaged as an appropriate therapeutic for Alzheimer through reduction of amyloid-beta aggregation. The solubilization of therapeutics using polymeric micelles facilitates an improved bioavailability and extended blood half-life. In this study, the optimum production condition for Anti-amyloid-beta (Anti-Aß) scFv was obtained. To increase the stability of plasma, Anti-Aß-loaded polymeric micelles were synthesized. METHODS: Escherichia coli SHuffle expression strain was used and purified by Ni-NTA. Pluronics P85 and F127 micelles were used for the Anti-Aß delivery and were characterized in terms of morphology, drug loading and drug release in phosphate buffer and artificial cerebrospinal fluid. The stability profile was quantified at 4°C over a 30 days storage period. The stability in human plasma was also evaluated. KEY FINDINGS: Proteins expressed in SHuffle resulted in increased levels of protein expression and solubility. Low critical micelle concentration value and high micelle encapsulation efficiency (<200 nm) achieved via direct dissolution method. Anti-Aß-loaded micelles were around 2.2-fold more stable than Anti-Aß in plasma solution. A sustained in-vitro release of Anti-Aß from micelles was observed. CONCLUSIONS: Results confirmed that Pluronic-micelles pose benefits as a nano-carrier to increase the stability of Anti-Aß scFvin in the plasma.
